A recent FiercePharma article discussed the massive settlement Bausch Health will pay for actions aimed at protecting their diabetes medication Glumetza. The Canadian drugmaker will pay $300 million for a 2019 lawsuit that claims the company paid off generic rivals so that the company could increase prices 800% for their type 2 diabetes drug. The class action lawsuit was driven by direct purchasers of the medication, and was set to go to trial in October.
Bausch to Dish Out $300M in Pay-to-Delay Settlement
The lawsuit claimed the company paid off generic rivals, allowing the company to increase prices 800%.
Sep 17, 2021
Recommended
Recommended
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
